Flaherty PFO Slides 071 as Selling Pressure Mounts 20260515 Bitdeer BTDR Q1 2026 Earnings Miss EPS 068 vs 037 Expected Stock Market Holds Steady as Investors Weigh Economic Signals on May 14 Mergers and Acquisitions Viewing Deals as Strategic Transformations Not Just Transactions Inogen INGN Q1 2026 Results Miss Estimates EPS 030 vs 029 DEE Development Engineers Reports 12 Decline in Q4 Net Profit Revenue Grows Amid Rising Costs Analog Devices Acquires Empower Semiconductor for 15 Billion to Strengthen AI Power Management Portfolio Fidelity D FDBC Q4 2025 Earnings Revenue NA Matching Views PutinXi Talks Could Revive Stalled Power of Siberia 2 Pipeline Amid Energy Market Turmoil Jobless Claims Remain Near Historic Lows Amid Tight Labor Market UK Government Pledges 120 Million to Boost Ceramics Industry Americans Face Stubborn Inflation Pressures as Memorial Day Weekend Spending Rises Travel Recreation and Food Lead Price Hikes Flipkart Achieves Record 200 Million SingleDay Sales During Festive Season Pharmaceutical Sector Outlook 2026 Key Themes and Investment Considerations PSIX Q1 2026 Earnings EPS Falls Short of Estimates by Over 52 Hour Loop Inc HOUR Q4 2024 Earnings Narrowing Losses in a Challenging Retail Environment RDNW Q1 2026 Earnings EPS Surprises to the Upside Despite Revenue NonDisclosure GLMD Q4 2025 Earnings EPS Misses Estimates Amid Development Stage Uncertainty Argan Inc AGX Q1 2026 Earnings EPS Surges 737 Above Estimates Shares Climb Nearly 2 MXCT Q1 2026 Earnings EPS Beats with 5098 Surprise Stock Rises 8 EP Q3 2025 Earnings Loss Per Share Reported Amid Ongoing Industry Headwinds SNSE Q1 2026 Earnings EPS Significantly Below Estimates as Company Invests in Pipeline Personalis Inc PSNL Q1 2026 Earnings EPS Misses Estimates but Stock Jumps 6 on LongTerm Optimism FUL Q1 2026 Earnings EPS Beats Estimates Shares Rise 228 NOAH Q3 2025 Earnings EPS of 326 Amid Market Headwinds US Government Drops Tax Claims Against Trump Organization in Broadened IRS Settlement MCRB Q1 2026 Earnings WiderthanExpected Loss as PreRevenue Biotech Continues RD Focus